Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
2011-01-25
2011-01-25
Whiteman, Brian (Department: 1635)
Chemistry: molecular biology and microbiology
Vector, per se
Reexamination Certificate
active
07875449
ABSTRACT:
Low molecular weight low molecular weight chitosan oligomers were able to self-assemble siRNA into nanosized particles, provide protection against enzymatic degradation, and mediate gene silencing that is stable over a long period of time in vitro. The control of structural variables in formulating complexes of siRNA with low molecular weight chitosans provides an efficient alternative delivery system for siRNA in vitro and in vivo.
REFERENCES:
patent: 3922260 (1975-11-01), Peniston et al.
patent: 6184037 (2001-02-01), Roland et al.
patent: 2003/0134810 (2003-07-01), Springate et al.
patent: 2003/0166594 (2003-09-01), Blum et al.
patent: 2005/0164964 (2005-07-01), Artursson et al.
patent: 2005/0170355 (2005-08-01), Artursson et al.
patent: 2007/0116767 (2007-05-01), Mohapatra et al.
patent: 2008/0085242 (2008-04-01), Artursson et al.
patent: 2009/0110719 (2009-04-01), Roy et al.
patent: WO-03030941 (2003-04-01), None
patent: WO-03092739 (2003-11-01), None
patent: WO-03092740 (2003-11-01), None
patent: WO-2004074314 (2004-09-01), None
patent: WO-2005113770 (2005-12-01), None
patent: WO-2007050643 (2007-05-01), None
patent: WO-2007059605 (2007-05-01), None
patent: WO-2008003329 (2008-01-01), None
Koping-Hoggard M et al., “Improved chitosan-mediated gene delivery based on easily dissociated chitosan polyplexes of highly defined chitosan oligomers”, Gene Therapy, Nature Publishing Group, vol. 11 No. 19 Oct. 2004 pp. 1441-1452. XP-002471182 ISSN: 0969-7128.
Katas H et al., “Development and characterisation of chitosan nanoparticles for siRNA delivery”, Journal of Controlled Release. Elsevier Science Publishers BV, Amsterdam NL vol. 115 No. 2 Oct. 2006 pp. 216-225 XP005705694 ISSN: 0168-3659 Available online Jul. 25, 2006.
Gao S, et al., “Targeting delivery of oligonucleotide and plasmid DNA to hepatocyte via galactosylated chitosan vector” European Journal of Pharmaceutics and BioPharmaceuticals, Elsevier Science Publishers BV. Amsterdam NL vol. 60 No. 3 Aug. 2005 pp. 327-334, XP004967314 ISSN: 0939-6411.
Lavertu et al., “High efficiency gene transfer using chitosan/DNA nanoparticles with specific combinations of molecular weight and degree of acetylation” Biomaterials, Elsevier Science Publishers BV, Barking GB, vol. 27 No. 27 Sep. 2006 pp. 4815-4824, XP005495427 ISSN: 0142-9612 Available online May 24, 2006.
Issa M M “Linear and Branched Chitosan Oligomers as Delivery Systems for pDNA and siRNA in vitro and in vivo” Nov 29, 2006 Uppsala University, Uppsala SE XP002471183 ISSN: 1651-6192 ISBN: 91-554-6747-4.
Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration—Dated Mar. 17, 2008—International Application No. PCT/EP2007/059740—International Filing Date—Sep. 14, 2007.
Meister G, et al., “Mechanisms of Gene Silencing by Double-stranded RNA” Nature 431(7006) (2004) pp. 343-349. Nature Publishing Group.
Sachse C, et al., “High-throughput RNA interference strategies for target discovery and validation by using synthetic short interfering RNAs: functional genomics investigations of biological pathways” Methods Enzymology 392(2005) pp. 242-277. Elsevier Inc.
Cejka D, et al. “Short interfering RNA (siRNA): tool or therapeutic?” Clinical Science. 110(1) (2006) 47-58. London, Great Britain.
Burkhardt B R, et al. “Efficient delivery of siRNA into cytokine-stimulated insulinoma cells silences Fas expression and inhibits Fas-mediated apoptosis” Federation of European Biochemical Societies Letters 580(2) (2006) pp. 553-560, Elsevier BV.
Devi GR “siRNA-based approaches in cancer therapy” Cancer Gene Therapy, (2006). 13PP 819-829 Nature Publishing Group published online Jan. 2, 2006.
Nishitsuji H, et al, “Effective Suppression of Human Immunodeficiency Virus Type 1 through a Combination of Short- or Long-Hairpin RNAs Targeting Essential Sequences for Retroviral Integration” J Virology. 80(15) (Aug. 2006) pp. 7658-7666. America Society for Microbiology.
Elman J, et al. “Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality” Nucleic Acids Res. 33(1) (2005) pp. 439-447 Oxford University Press.
Chen X., et al. “Chemical modification of gene silencing oligonucleotides for drug discovery and development” Drug Discovery Today. 10(8) (Apr. 2005) pp. 587-593.
Lorenz C, et al. “Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells” Bioorganic & Medicinal Chemistry Letters 14(19) (2004) pp. 4975-4977. Elsevier Ltd.
Dalby B, et al. “Advanced transfection with Lipofectamine 2000 reagent: primary neurons, siRNA, and high-throughput applications” Methods. 33(2) (2004) pp. 95-103 Elsevier Inc.
Hassani Z, et al “Lipid-mediated siRNA delivery down-regulates exogenous gene expression in the mouse brain at picomolar levels” J Gene Medicine 7(2) (2005) pp. 198-207. Published online Oct. 28, 2004 John Wiley & Sons, Ltd.
Urban-Klein B, et al. “RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-compIexed siRNA in vivo” Gene Therapy 12(5) (2005) pp. 461-466 Nature Publishing Group published online Dec. 23, 2004.
Zhou J, et al. “PAMAM dendrimers for efficient siRNA delivery and potent gene silencing” Chem Commun (Camb).22) (2006) pp. 2362-2364 Royal Society of Chemistry, published as an Advance Article online May 10, 2006.
Leng Q, et al. “Highly branched HK peptides are effective carriers of siRNA” J Gene Medicine 7(7) (2005) pp. 977-986 John Wiley & Sons published online Mar. 17, 2005.
Chen HT et al. Cytotoxicity, hemolysis, and acute in vivo toxicity of dendrimers based on melamine, candidate vehicles for drug delivery, J American Chemical Society 126(32) (2004) pp. 10044-10048. Published on web Jul. 22, 2004.
Roy K, et al. “Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy” Nature Medicine 5(4) (Apr. 1999) pp. 387-391.
Koping-Hoggard M, et al. “Chitosan as a nonviral gene delivery system. Structure- property relationships and characteristics compared with polyethylenimine in vitro and after lung administration in vivo” Gene Therapy 8(14) (2001) pp. 1108-1121 Nature Publishing Group.
Zhang W, et al. “Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NSI gene” Nature Medicine 11(1) (Jan. 2005) pp. 56-62. Published online Dec. 26, 2004.
Elbashir S M, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells, Nature. 411(May 24, 2001) pp. 494-498. Macmillan Magazines Ltd.
Honkakoski P, et al. “A novel drug-regulated gene expression system based on the nuclear receptor constitutive androstane receptor (CAR)”, Pharmaceutical Research. 18(2) (2001) pp. 146-150 Plenum Publishing Corp.
Lappalainen K., et al. “Comparison of cell proliferation and toxicity assays using two catonic liposomes” Pharmaceutical Research 11(8) (1994) pp. 1127-1131 Plenum Publishing Corp.
Janes K A, et al. “Polysaccharide colloidal particles as delivery systems for macromolecules” Advanced Drug Delivery Reviews 47(1) (2001) pp. 83-97 Elsevier Science BV.
Liu X., et al. “The influence of polymeric properties on chitosan/ siRNA nanoparticle formulation and gene silencing” Biomaterials 28 (2007) 1280-1288 Elsevier Ltd.
Issa M M , et al. Chitosan Oligomers as siRNA delivery systems in vitro ASGT abstract 1023 Poster Session III: Oligonucleiotide Therapies II Jun. 2, 2007.
Tommeraas K, et al. “Preparation and characterization of chitosans with oligosaccharide branches” Carbohydrate Research vol. 337 (2002) pp. 2455-2462 Elsevier Science Ltd.
Strand S P, et al. “Influence of chit
Artursson Per Artur Sven
Issa Mohamed Mahmoud
Strand Sabina Prochazkova
Varum Kjell Morten
FMC Biopolymer AS
FMC Corporation
Whiteman Brian
LandOfFree
Oligonucleotide non-viral delivery systems does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oligonucleotide non-viral delivery systems, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oligonucleotide non-viral delivery systems will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2712632